130 related articles for article (PubMed ID: 22302034)
21. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
22. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
[TBL] [Abstract][Full Text] [Related]
23. APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment.
Sjödin S; Andersson KK; Mercken M; Zetterberg H; Borghys H; Blennow K; Portelius E
Alzheimers Res Ther; 2015 Dec; 7(1):77. PubMed ID: 26689589
[TBL] [Abstract][Full Text] [Related]
24. The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease.
Portelius E; Fortea J; Molinuevo JL; Gustavsson MK; Andreasson U; Sanchez-Valle R
Mol Med Rep; 2012 Apr; 5(4):1111-5. PubMed ID: 22307680
[TBL] [Abstract][Full Text] [Related]
25. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
[TBL] [Abstract][Full Text] [Related]
26. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry.
Portelius E; Westman-Brinkmalm A; Zetterberg H; Blennow K
J Proteome Res; 2006 Apr; 5(4):1010-6. PubMed ID: 16602710
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid.
Portelius E; Brinkmalm G; Tran A; Andreasson U; Zetterberg H; Westman-Brinkmalm A; Blennow K; Ohrfelt A
Exp Neurol; 2010 Jun; 223(2):351-8. PubMed ID: 19559702
[TBL] [Abstract][Full Text] [Related]
28. Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease.
Zetterberg H
Scand J Clin Lab Invest; 2009; 69(1):18-21. PubMed ID: 19199126
[TBL] [Abstract][Full Text] [Related]
29. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
30. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.
Siemers ER; Dean RA; Friedrich S; Ferguson-Sells L; Gonzales C; Farlow MR; May PC
Clin Neuropharmacol; 2007; 30(6):317-25. PubMed ID: 18090456
[TBL] [Abstract][Full Text] [Related]
31. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
[TBL] [Abstract][Full Text] [Related]
32. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
[TBL] [Abstract][Full Text] [Related]
33. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).
Lanz TA; Hosley JD; Adams WJ; Merchant KM
J Pharmacol Exp Ther; 2004 Apr; 309(1):49-55. PubMed ID: 14718585
[TBL] [Abstract][Full Text] [Related]
34. Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases.
Böhme L; Hoffmann T; Manhart S; Wolf R; Demuth HU
Biol Chem; 2008 Aug; 389(8):1055-66. PubMed ID: 18979630
[TBL] [Abstract][Full Text] [Related]
35. Microchip electrophoresis profiling of Aβ peptides in the cerebrospinal fluid of patients with Alzheimer's disease.
Mohamadi MR; Svobodova Z; Verpillot R; Esselmann H; Wiltfang J; Otto M; Taverna M; Bilkova Z; Viovy JL
Anal Chem; 2010 Sep; 82(18):7611-7. PubMed ID: 20722394
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
37. Distinct deposition of amyloid-β species in brains with Alzheimer's disease pathology visualized with MALDI imaging mass spectrometry.
Kakuda N; Miyasaka T; Iwasaki N; Nirasawa T; Wada-Kakuda S; Takahashi-Fujigasaki J; Murayama S; Ihara Y; Ikegawa M
Acta Neuropathol Commun; 2017 Oct; 5(1):73. PubMed ID: 29037261
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
Carlson C; Estergard W; Oh J; Suhy J; Jack CR; Siemers E; Barakos J
Alzheimers Dement; 2011 Jul; 7(4):396-401. PubMed ID: 21784350
[TBL] [Abstract][Full Text] [Related]
39. Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia.
Albertini V; Benussi L; Paterlini A; Glionna M; Prestia A; Bocchio-Chiavetto L; Amicucci G; Galluzzi S; Adorni A; Geroldi C; Binetti G; Frisoni GB; Ghidoni R
Electrophoresis; 2012 Dec; 33(24):3738-44. PubMed ID: 23161113
[TBL] [Abstract][Full Text] [Related]
40. Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry.
Portelius E; Lashley T; Westerlund A; Persson R; Fox NC; Blennow K; Revesz T; Zetterberg H
Neurodegener Dis; 2015; 15(1):50-7. PubMed ID: 25591542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
